跳到內容

跳到副選單

耶和華見證人

中文繁體(國語)

血液科——腫瘤醫學

貧血處置

Intravenous iron in oncology.

Auerbach M, Ballard H.

出處‎: J Natl Compr Canc Netw 2008;6(6):585-92.

檢索‎: PubMed 18597712

http://www.ncbi.nlm.nih.gov/pubmed/18597712

Intravenous iron: from anathema to standard of care.

Auerbach M, Coyne D, Ballard H.

出處‎: Am J Hematol 2008;83(7):580-8.

檢索‎: PubMed 18273906

DOI碼‎: 10.1002/ajh.21154

http://www.ncbi.nlm.nih.gov/pubmed/18273906

What is the right balance between iron and erythropoiesis stimulating agents in chemotherapy induced anemia?

Auerbach M, Glaspy J.

出處‎: Eur J Clin Med Oncol 2009;1(1):1-6.

檢索‎: ISSN 1759-8958

http://www.worldcat.org/oclc/773316108

The safety of intravenous iron preparations: systematic review and meta-analysis.

Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A.

出處‎: Mayo Clin Proc 2015;90(1):12-23.

檢索‎: PubMed 25572192

DOI碼‎: 10.1016/j.mayocp.2014.10.007

http://www.ncbi.nlm.nih.gov/pubmed/25572192

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

出處‎: Am J Hematol 2011;86(9):762-7.

檢索‎: PubMed 21850658

DOI碼‎: 10.1002/ajh.22111

http://www.ncbi.nlm.nih.gov/pubmed/21850658

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF.

出處‎: J Clin Oncol 2008;26(10):1611-8.

檢索‎: PubMed 18375890

DOI碼‎: 10.1200/JCO.2006.10.4620

http://www.ncbi.nlm.nih.gov/pubmed/18375890

Acute myeloid leukemia in Jehovah’s Witnesses.

Brown NM, Keck G, Ford PA.

出處‎: Leuk Lymphoma 2008;49(4):817-20.

檢索‎: PubMed 18398752

DOI碼‎: 10.1080/10428190801911670

http://www.ncbi.nlm.nih.gov/pubmed/18398752

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

出處‎: Cancer 2012;118(3):848-55.

檢索‎: PubMed 21751205

DOI碼‎: 10.1002/cncr.26341

http://www.ncbi.nlm.nih.gov/pubmed/21751205

Management of anemia in cancer patients.

Calabrich A, Katz A.

出處‎: Future Oncol 2011;7(4):507-17.

檢索‎: PubMed 21463140

DOI碼‎: 10.2217/fon.11.24

http://www.ncbi.nlm.nih.gov/pubmed/21463140

The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products.

Ciurea S, Beri R, Dobogai L, Chunduri S, Mahmud N, Rondelli D, Peace D.

出處‎: Bone Marrow Transplant 2006;37(3):325-7.

檢索‎: PubMed 16314850

http://www.ncbi.nlm.nih.gov/pubmed/16314850

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy.

Crary SE, Hall K, Buchanan GR.

出處‎: Pediatr Blood Cancer 2011;56(4):615-9.

檢索‎: PubMed 21298748

DOI碼‎: 10.1002/pbc.22930

http://www.ncbi.nlm.nih.gov/pubmed/21298748

Update on safety of ESAs in cancer-induced anemia.

Glaspy J.

出處‎: J Natl Compr Canc Netw 2012;10(5):659-66.

檢索‎: PubMed 22570294

http://www.ncbi.nlm.nih.gov/pubmed/22570294

Parenteral iron therapy in cancer-associated anemia.

Henry DH.

出處‎: Hematology Am Soc Hematol Educ Program 2010;2010:351-6.

檢索‎: PubMed 21239818

DOI碼‎: 10.1182/asheducation-2010.1.351

http://www.ncbi.nlm.nih.gov/pubmed/21239818

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B

出處‎: Source: Cochrane Database Syst Rev 2016;2:CD009624.

檢索‎: PubMed 26845108

DOI碼‎: 10.1002/14651858.CD009624.pub2

http://www.ncbi.nlm.nih.gov/pubmed/26845108

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

出處‎: Support Care Cancer 2012;20(1):159-65.

檢索‎: PubMed 21359879

DOI碼‎: 10.1007/s00520-010-1083-7

http://www.ncbi.nlm.nih.gov/pubmed/21359879

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

出處‎: J Clin Oncol 2008;26(10):1619-25.

檢索‎: PubMed 18375891

DOI碼‎: 10.1200/JCO.2007.12.2051

http://www.ncbi.nlm.nih.gov/pubmed/18375891

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

出處‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

檢索‎: PubMed 21972052

DOI碼‎: 10.1007/s00432-011-1072-3

http://www.ncbi.nlm.nih.gov/pubmed/21972052

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

出處‎: Ann Oncol 2013;24(2):475-82.

檢索‎: PubMed 23071262

DOI碼‎: 10.1093/annonc/mds338

http://www.ncbi.nlm.nih.gov/pubmed/23071262

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, D­íez-Campelo M, et al.

出處‎: Eur J Haematol 2015 Sep. [Epub ahead of print]

檢索‎: PubMed 26341961

DOI碼‎: 10.1111/ejh.12679

http://www.ncbi.nlm.nih.gov/pubmed/26341961


JW.ORG​網站​內​的​醫療​資訊​主要​是​提供​給​醫生​及​醫療人員​參考,而​不​是​要​提供​診斷​建議​或​推薦​某​種​醫療​方法,也​不​是​要​取代​專業​的​醫療​護理。網站​上​引用​的​許多​醫學​文章​都​不​是​耶和華見證人​出版​的,但​當​中​提​到​了​許多​替代​輸​血​的​療法,這些​醫療​策略​很​值得​醫生​參考。每​一​個​專業​醫療人員​都​有​責任​經常​吸收​最​新​的​醫療​資訊,討論​最​適合​病人​的​醫療​方法。他們​也​要​根據​病人​的​病情、意願、價值觀​和​信仰​來​協助​病人​選擇​最佳​的​醫療​方式。本​網站​所​提供​的​醫療​策略​不​一定​適用​於​每​一​個​病人。

給​病人​的​建議:當​你​感到​身體​不適,要​立刻​尋求​醫生​的​幫助,也​要​聽取​醫生​以及​其他​專業​醫療人員​的​建議。

使用​本​網站​即​表示​你​接受​本使用​條款的​全部​內容。